Merck & Company, Inc. Common Stock (new) (MRK) is listed on NYSE in Pharmaceutical Stocks. It is $148.31, -0.82%, with a $365.9B market cap. RSI is 64.1, near overbought. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 64.1 Near Overbought
Market Cap $365.9B
Volume 7.9M
Fundamentals — 10-Q Q2 2026
Revenue $32.9B
Net Income $-5.6B
EPS $-2.26
Gross Margin 73.9%
Net Margin -16.9%
Debt / Equity 1.2x
P/E Ratio -65.6x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Guindo Chirfi | EVP, Access, Policy & Comms | Sell | 10,000 | $135.00 | $1.4M | 2026 Aug 13 |
| Zachary Jennifer | EVP, General Counsel | Sell | 80,315 | $133.46 | $10.7M | 2026 Aug 12 |
| Deluca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | 45,320 | $131.12 | $5.9M | 2026 Aug 12 |
| Deluca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | 6,050 | $130.38 | $788,773 | 2026 Aug 6 |
| Guindo Chirfi | EVP, Access, Policy & Comms | Sell | 15,000 | $131.00 | $2.0M | 2026 Aug 6 |
| Maraldo David R. | EVP & Pres. MMD | Sell | 18,706 | $128.72 | $2.4M | 2026 Aug 5 |
| Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 52,847 | $128.77 | $6.8M | 2026 Aug 5 |
| Downing Cristal N | Chief Comm. & Public Afrs Ofcr | Sell | 7,085 | $87.00 | $616,395 | 2025 Nov 10 |
| Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 8,614 | $83.59 | $720,044 | 2025 Nov 3 |
| Smart Dalton E. III | SVP Fin. - Global Controller | Sell | 4,262 | $82.76 | $352,723 | 2025 Apr 25 |
| Oosthuizen Johannes Jacobus | President, U.S. Market | Sell | 8,500 | $84.09 | $714,765 | 2025 Feb 19 |
| Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 6,000 | $85.34 | $512,040 | 2025 Feb 13 |
| Downing Cristal N | Chief Comm. & Public Afrs Ofcr | Sell | 2,361 | $88.76 | $209,562 | 2025 Feb 6 |
| Thulin Inge G | Director | Buy | 2,833 | $88.25 | $250,000 | 2025 Feb 6 |
| Baker Douglas M JR | Director | Buy | 15,000 | $88.50 | $1.3M | 2025 Feb 5 |
| Davis Robert M | Chairman, CEO & President | Sell | 235,021 | $125.68 | $29.5M | 2024 Feb 14 |
| Litchfield Caroline | EVP & CFO | Sell | 38,291 | $125.50 | $4.8M | 2024 Feb 14 |
| Romanelli Joseph | President, Human Health Int?l | Sell | 1,000 | $124.89 | $124,890 | 2024 Feb 13 |
| Li Dean Y | Executive VP & President, MRL | Sell | 14,702 | $125.50 | $1.8M | 2024 Feb 9 |
| Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 1,451 | $127.57 | $185,104 | 2024 Feb 7 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $255.53 | 48.7 | $451.6B |
| | $244.60 | 46.0 | $15.9B |
| | $112.44 | 58.9 | $195.8B |
| | $27.96 | 64.8 | $159.3B |
| | $794.08 | 58.2 | $82.1B |
| | $45.60 | 41.8 | -- |
Take MRK further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put MRK in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Merck & Company, Inc. Common Stock (new) next reports.
Set alerts on MRK
Get notified when Merck & Company, Inc. Common Stock (new) hits your price targets or technical conditions are met.
Get Started Free